| Topic |
Required information |
| Definition |
Cancerous or abnormal or malignant cells, AND anatomical location of origin |
| Incidence or Prevalence |
Statistics accurate within 5 years: Approximately 13,000 new cases per year in the United States, OR 0.6% lifetime risk, OR equivalent numbers for website country of origin, as referenced by national cancer statistic reporting agencies |
| Etiology or Risk Factors |
HPV infection as major risk factor, AND at least one additional risk factor that either: a) increases risk in with HPV (high parity, tobacco exposure, long-term oral contraceptives, OR b) increases risk of HPV infection (immune suppression, sexual activity at a young age or greater life time number of sexual partners) |
| Prevention |
Method to protect against HPV infection (e.g. vaccination), AND regular screening at appropriate ages |
| Symptoms |
Must include abnormal vaginal bleeding or discharge, AND pelvic pain or pain during sexual intercourse |
| Detection or workup |
Tissue diagnosis by biopsy; may include discussion of screening tests leading to colposcopy and biopsy |
| Staging |
Staging is from 0 or I – IV based on lesion size, depth and extent of spread (stage-specific definitions not required) |
| Treatment |
Dependent on staging and clinical picture, AND treatments may or may not include surgery, radiation, or chemotherapy, AND minimal description of treatment and when used (e.g. early vs. later stage) |
| Prognosis |
Dependent on stage, AND a survival statistic overall or by stage, as referenced by national cancer statistic reporting agencies |
| Treatment Side-effects |
At least one specific side effect discussed |
| Follow up |
Types of follow up that may be required given treatment type, OR reasonable post-treatment screening schedule |
